Products for Research Use Only

Fosamprenavir-13C6

CAT: 0804-HY-78726S2Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-78726S2Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fosamprenavir-13C6 is the 13C-labeled Fosamprenavir. Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection[1][2][3].
Product Name Alternative
Amprenavir phosphate-13C6; GW 433908-13C6
UNSPSC
12352005
Target
Drug Intermediate; HIV; HIV Protease; Isotope-Labeled Compounds
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O)(O)=O)CN(S(=O)([13C]3=[13C][13C]=[13C](N)[13C]=[13C]3)=O)CC(C)C
Molecular Formula
C19 13C6H32N3O9PS
Molecular Weight
587.53
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40 (7-8) :1301-10.|[3]Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1 (Suppl 1) :S1-S11.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
HIV-1